We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
-7.76%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.41B
AUM Growth
+$104M
Cap. Flow
+$94.2M
Cap. Flow %
6.7%
Top 10 Hldgs %
55.6%
Holding
106
New
20
Increased
33
Reduced
17
Closed
29

Top Buys

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$46.7M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$26.7M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$26.5M
4
TNDM icon
Tandem Diabetes Care
TNDM
+$21M
5
ABMD
Abiomed Inc
ABMD
+$18.7M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$49M
2
HCA icon
HCA Healthcare
HCA
+$27.9M
3
MASI
Masimo
MASI
+$27.2M
4
ARKG icon
ARK Genomic Revolution ETF
ARKG
+$21.6M
5
RCM
R1 RCM Inc. Common Stock
RCM
+$17.5M

Sector Composition

Rank Sector Weight
1 Healthcare 70.04%
2 Miscellaneous 29.08%
3 Industrials 0.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BOLT icon
76
Bolt Biotherapeutics
BOLT
$7.34M
$63.6K ﹤0.01%
+1,559
New +$60.5K
CBIO
77
Crescent Biopharma
CBIO
$659M
$60.1K ﹤0.01%
1,006
– –
ADAP
78
DELISTED
Adaptimmune Therapeutics
ADAP
– –
-237,086
Closed -$488K
ARKG icon
79
ARK Genomic Revolution ETF
ARKG
$1.88B
– –
-470,506
Closed -$21.6M
ASMB icon
80
Assembly Biosciences
ASMB
$694M
– –
-23,333
Closed -$577K
ASND icon
81
Ascendis Pharma A/S
ASND
$16.3B
– –
-417,172
Closed -$49M
AUTL
82
Autolus Therapeutics
AUTL
$623M
– –
-371,540
Closed -$1.55M
BIIB icon
83
CALL
Biogen
BIIB
$32.3B
– –
-140,000
Closed -$29.5M
CYCN icon
84
Cyclerion Therapeutics
CYCN
$17.7M
– –
-18,598
Closed -$413K
ENSG icon
85
The Ensign Group
ENSG
$10.1B
– –
-10,397
Closed -$936K
EWT icon
86
PUT
iShares MSCI Taiwan ETF
EWT
$11.7B
– –
-100,000
Closed -$6.14M
EXEL icon
87
Exelixis
EXEL
$13.5B
– –
-203,156
Closed -$4.61M
HCA icon
88
HCA Healthcare
HCA
$90.5B
– –
-111,440
Closed -$27.9M
IRTC icon
89
iRhythm Holdings
IRTC
$3.96B
– –
-27,047
Closed -$4.26M
IWO icon
90
PUT
iShares Russell 2000 Growth ETF
IWO
$14.8B
– –
-1,700
Closed -$435K
KOD icon
91
Kodiak Sciences
KOD
$2.37B
– –
-91,200
Closed -$704K
KOD icon
92
PUT
Kodiak Sciences
KOD
$2.37B
– –
-181,200
Closed -$1.4M
MCK icon
93
McKesson
MCK
$104B
– –
-52,375
Closed -$16.1M
MREO
94
Mereo BioPharma
MREO
$40.3M
– –
-370,170
Closed -$415K
MRK icon
95
Merck
MRK
$366B
– –
-9,483
Closed -$841K
PGNY icon
96
PUT
Progyny
PGNY
$1.99B
– –
-50,000
Closed -$2.57M
SPRO icon
97
Spero Therapeutics
SPRO
$69.9M
– –
-59,639
Closed -$519K
TECH icon
98
Bio-Techne
TECH
$11.3B
– –
-4,248
Closed -$460K
TECX
99
Tectonic Therapeutic
TECX
$696M
– –
-24,614
Closed -$390K
KRTX
100
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
– –
-15,934
Closed -$2.02M
1 2 3
4
5

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q2 2022 Portfolio in Review

As of Q2 2022, Eversept Partners held 106 positions worth $1.41B, up 8% from $1.3B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Eversept Partners deployed $94.2M of net new capital in Q2 2022, opening 20 new positions and adding to 33 existing holdings. Its largest new stake was Sanofi: 879,460 shares worth $44M.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, down from 79% a quarter earlier, followed by Miscellaneous and Industrials.

On the sell side, the largest reduction was Masimo, an estimated $27.2M trimmed.

  • Eversept Partners's largest Q2 2022 buy was Sanofi: 879,460 shares worth $44M.
  • Eversept Partners added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2022, an estimated $26.5M increase.
  • Eversept Partners's biggest Q2 2022 reduction was Masimo, cutting an estimated $27.2M.
  • Eversept Partners fully exited Ascendis Pharma A/S in Q2 2022, selling an estimated $49M.
  • Eversept Partners's ten largest holdings make up 56% of its $1.41B portfolio in Q2 2022.
  • Eversept Partners opened 20 new positions and closed 29 in Q2 2022.
  • Eversept Partners's portfolio value rose 8% quarter-over-quarter to $1.41B.

Based on Eversept Partners's 13F filing for Q2 2022, filed 15 Aug 2022.